Peter Lawson
Stock Analyst at Barclays
(1.24)
# 3,528
Out of 4,931 analysts
97
Total ratings
35.71%
Success rate
-14.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $5.48 | -45.26% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $37.39 | +6.98% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.61 | +86.34% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $0.98 | +104.06% | 4 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $1 → $0.46 | $0.08 | +454.22% | 3 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $4.10 | +144.20% | 3 | May 13, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $5 → $4 | $2.64 | +51.52% | 7 | May 12, 2025 | |
| XNCR Xencor | Maintains: Underweight | $22 → $6 | $7.32 | -18.03% | 2 | May 8, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $32 → $11 | $5.96 | +84.56% | 1 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $32 → $16 | $6.24 | +156.41% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $7.46 | +101.07% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $9.28 | +50.86% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.63 | +84.05% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.65 | +81.82% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.30 | +207.69% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $34.95 | +71.67% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $3.49 | +387.11% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $12.72 | +159.43% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $31.93 | +106.70% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $10.07 | +207.85% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $6.61 | +96.67% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.86 | +483.43% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $2.10 | +66.67% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $95.50 | +282.20% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $37.06 | +24.12% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $21.75 | +1,968.97% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.49 | +1,707.23% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $55.96 | -19.59% | 2 | Jan 23, 2018 |
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $5.48
Upside: -45.26%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $37.39
Upside: +6.98%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.61
Upside: +86.34%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $0.98
Upside: +104.06%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Underweight
Price Target: $1 → $0.46
Current: $0.08
Upside: +454.22%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $4.10
Upside: +144.20%
Iovance Biotherapeutics
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.64
Upside: +51.52%
Xencor
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $7.32
Upside: -18.03%
Kura Oncology
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $5.96
Upside: +84.56%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $6.24
Upside: +156.41%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $7.46
Upside: +101.07%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $9.28
Upside: +50.86%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.63
Upside: +84.05%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.65
Upside: +81.82%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.30
Upside: +207.69%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $34.95
Upside: +71.67%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $3.49
Upside: +387.11%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $12.72
Upside: +159.43%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $31.93
Upside: +106.70%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $10.07
Upside: +207.85%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $6.61
Upside: +96.67%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.86
Upside: +483.43%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.10
Upside: +66.67%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $95.50
Upside: +282.20%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $37.06
Upside: +24.12%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $21.75
Upside: +1,968.97%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.49
Upside: +1,707.23%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $55.96
Upside: -19.59%